Petefészekrák: vizsgálatok itt: Csehország
17 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Where
- Brno-Stred, Ostrava, Prague
- Életkor
- 18 év and over
- People
- 770 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00 - 3. fázisTaking peopleA Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Where
- Brno-Stred, Hradec Králové, Ostrava, Prague
- Életkor
- 18 év and over
- People
- 900 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00 - 3. fázisTaking peopleA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Brno, Nový Jiín, Olomouc, Prague, Zlín
- Életkor
- 18 év and over
- People
- 1630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00 - 3. fázisTaking peopleStudy to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Where
- Hradec Králové, Nový Jičín, Prague
- Életkor
- 18 év and over
- People
- 688 worldwide
- Run by
- Genmab
See details and how to joinNCT07564141 · EU 2025-524202-15-00 - 3. fázisTaking peopleStudy of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Where
- Ostrava, Prague
- Életkor
- 18 év and over
- People
- 582 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00 - 2/3. fázisTaking peopleA Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Where
- Brno-Stred, Novy Hradec Kralove, Prague
- Életkor
- 18 év and over
- People
- 860 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00 - 2. fázisTaking peopleA Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
- Where
- Ostrava, Prague
- Életkor
- 18 év and over
- People
- 640 worldwide
- Run by
- North Eastern German Society of Gynaecological Oncology
See details and how to joinNCT05460000 · EU 2022-502559-69-01 - 2. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Where
- Brno-Stred, Hradec Králové, Ostrava, Prague
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- AbbVie
See details and how to joinNCT07059845 · EU 2025-521606-18-00 - 3. fázisTaking peopleStudy to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
- Where
- Brno-Stred, Hradec Králové, Nový Jičín, Olomouc, Ostrava, Prague
- Életkor
- 18 év and over
- People
- 544 worldwide
- Run by
- Genmab
See details and how to joinNCT07225270 · EU 2025-522167-15-00 - No phaseTaking peopleInnovative Ovarian Cancer Biomarker Assays
- Where
- Prague
- Életkor
- 35 év and over
- People
- 2080 worldwide
- Run by
- National and Kapodistrian University of Athens
See details and how to joinNCT07693894 - No phaseTaking peopleCanRisk-Based Ovarian Cancer Risk Assessment Versus Standard Practice (DISARM CSA)
- Where
- Prague
- Életkor
- 18 év to 75 év
- People
- 2130 worldwide
- Run by
- Instituto Portugues Oncologia de Lisboa Francisco Gentil
See details and how to joinNCT07809659 - 3. fázisTaking peoplePrehabilitation in Gynaecological Cancer Patients
- Where
- Prague
- Életkor
- 18 év to 85 év
- People
- 64
- Run by
- Charles University, Czech Republic
See details and how to joinNCT04789694 - 3. fázisTaking peopleAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Where
- Brno-Stred, Hradec Králové, Nový Jičín, Olomouc, Prague
- Életkor
- 18 év and over
- People
- 1100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07218809 · EU 2025-520466-22-00 - No phaseTaking peopleA Prospective Multicenter Diagnostic Biomarker Study to Discriminate Borderline From Stage I Invasive Ovarian Cancer
- Where
- Prague
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- KU Leuven
See details and how to joinNCT06709872 - 2. fázisTaking peopleCATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Where
- Nový Jičín, Ostrava, Prague
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- TORL Biotherapeutics, LLC
See details and how to joinNCT06690775 · EU 2024-517190-24-00 - 3. fázisTaking peopleNiraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
- Where
- Brno, Prague
- Életkor
- 18 év and over
- People
- 970 worldwide
- Run by
- AGO Study Group
See details and how to joinNCT05009082 · EU 2024-516066-11-00 - No phaseTaking peopleUltrasound-guided Tru-cut Biopsy in Patients with Suspected Ovarian Cancer: Adequacy, Accuracy, Safety and Patient Assessment.
- Where
- Hradec Králové
- Életkor
- 18 év and over
- People
- 30
- Run by
- University Hospital Hradec Kralove
See details and how to joinNCT06689605